CAR T-Cell Therapy Market (By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others; By Indication: Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Others; By End User: Hospitals, Cancer Treatment Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market 

5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type

8.1. CAR T-Cell Therapy Market, by Drug Type, 2023-2032

8.1.1 Axicabtagene Ciloleucel

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Tisagenlecleucel

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Brexucabtagene Autoleucel

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global CAR T-Cell Therapy Market, By Indication

9.1. CAR T-Cell Therapy Market, by Indication, 2023-2032

9.1.1. Lymphoma

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Acute Lymphocytic Leukemia

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Chronic Lymphocytic Leukemia (CLL)

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Multiple Myeloma (MM)

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global CAR T-Cell Therapy Market, By End User 

10.1. CAR T-Cell Therapy Market, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Cancer Treatment Centers

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.1.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Forecast, by End User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Forecast, by End User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.2.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Forecast, by End User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Forecast, by End User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Forecast, by End User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Forecast, by End User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.3.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Forecast, by End User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Forecast, by End User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Forecast, by End User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Forecast, by End User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Forecast, by End User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Forecast, by End User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Forecast, by End User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Forecast, by End User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Forecast, by End User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Forecast, by End User (2020-2032)

Chapter 12. Company Profiles

12.1. Kolon TissueGene, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. JCR Pharmaceuticals Co., Ltd.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Kolon TissueGene, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. JCR Pharmaceuticals Co., Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. MEDIPOST

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. PHARMICELL Co., Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ANTEROGEN. CO., LTD

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb Company

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Novartis AG

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Gilead Sciences, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample